Purpose: To compare the therapeutic efficacy and safety of newly developed preservative-
free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solutions and a …

Purpose: To assess whether dorzolamide 2%–timolol 0.5%(D/T) and/or brimonidine 0.2%–
timolol 0.5%(B/T) alters retinal vascular autoregulation (RVA) and seated ocular perfusion …

Purpose To describe pooled efficacy and safety data from two phase 3 studies comparing
brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC) with its component …

The effect on intraocular pressure (IOP) of a 2-week washout following long-term ocular
therapy with topical levobunolol or timolol for an average period of 30 months was …

PURPOSE: To measure the relative efficacy of brinzolamide hydrochloride 1% ophthalmic
suspension, a new carbonic anhydrase inhibitor, compared with the currently used …

Purpose To evaluate the clinical efficiency and tolerability of brimonidine and dorzolamide
twice daily as an adjunctive therapy for glaucoma patients with an inadequate response to …

We compared the efficacy and safety of a new fixed combination of timolol
0.5%/dorzolamide 2%/brimonidine 0.2% in ophthalmic solution versus a fixed combination …

PURPOSE: Topical beta-blocker treatment is routine therapy in the management of patients
with glaucoma. Therapy results in systemic absorption, however, the degree of reduction of …

OBJECTIVE: To estimate the intraocular pressure (IOP)–lowering effect of 2% dorzolamide
or 0.005% latanoprost when added to 0.5% timolol. DESIGN: Meta-analysis of randomized …

Background: To determine the adjunctive 24-h efficacy obtained with brinzolamide/timolol,
or brimonidine/timolol fixed combinations (FCs) in open-angle glaucoma patients …